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Abstract
The ability of the liver to restore its original volume following tissue loss has been 
associated with the Hippo‐YAP1 pathway, a key controller of organ size. Yes‐asso-
ciated protein 1 (YAP1)—a growth effector usually restrained by Hippo signaling—
is believed to be of particular importance; however, its role in liver regeneration 
remains ill‐defined. To explore its function, we knocked down YAP1 prior to stand-
ard 70%‐hepatectomy (sHx) using a hepatocyte‐specific nanoformulation. 
Knockdown was effective during the major parenchymal growth phase (S‐phase/M‐
phase peaks at 32 hours/48 hours post‐sHx). Liver weight gain was completely sup-
pressed by the knockdown at 32 hours, but was reaccelerated toward 48 hours. 
Likewise, proliferative markers, Ccna2/b2 and YAP1 target gene expression were 
downregulated at 32 hours, but re‐elevated at 48 hours post‐sHx. Nonetheless, 
knockdown slightly compromised survival after sHx. When assessing a model of 
resection‐induced liver failure (extended 86%‐hepatectomy, eHx) featuring deficient 
S‐ and M‐phase progression, YAP1 was not induced at 32 hours, but upregulated at 
48 hours post‐eHx, confirming its dissociation from M‐phase regulation. Therefore, 
YAP1 is vital to push hepatocytes into cycle and through the S‐phase, but is not re-
quired for further cell cycle progression during liver regeneration. The examination 
of YAP1 in human livers suggested its function is conserved in the regenerating 
mammalian liver.
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1 |  INTRODUCTION
The vital functions of the liver require steady maintenance. 
Consequently, the liver is equipped with a unique regenera-
tive capacity and can regrow its original mass following ex-
tensive tissue loss. After surgical resection, the human liver 
regains normal function within 2‐3 weeks, while liver volume 
is completely restored after a few months.1 In mouse, partial 
70%‐hepatectomy (sHx, the standard model of liver regen-
eration) induces efficient regeneration leading to a complete 
volume regain within a week.2
The reconstitution of the exact liver volume following 
tissue loss points to an optimal liver‐size‐to‐body‐size ratio 
required for robust long‐term function. On the other hand, 
the liver continues to provide key functions also after tissue 
loss. If tissue loss, however, is too extensive, the liver rem-
nant loses the ability to regrow, leading to liver failure and 
eventually death. In mouse, massive resection (ie, 90%) of 
the liver causes 100% mortality within 2 days, while mortal-
ity is at ~30% following extended 86%‐hepatectomy (eHx), 
with survivors displaying metabolic liver dysfunction (hyper-
bilirubinemia, hypoalbuminemia, persisting steatosis) and a 
proliferative arrest in hepatocytes.2,3 In humans, resection‐in-
duced liver failure is known as the small‐for‐size syndrome 
(SFSS), likewise features metabolic as well as regenerative 
insufficiency,3 and is the most frequent cause of postopera-
tive death.4 Therefore, liver size is a key determinant of liver 
function, with an optimal volume for sound function and a 
minimal volume to sustain vital function under stress.
The most prominent pathway regulating organ size is the 
Hippo‐YAP1 axis. In brief, the MST1/2 and downstream 
LATS1/2 kinases are the conserved regulators of yes‐associ-
ated protein 1 (YAP1) to restrain its activity via phosphory-
lation‐induced degradation. Upon triggers such as the loss of 
cell‐cell contact, disturbed cell polarity, or mechanical stress, 
MST1/2‐LATS1/2 activities decline, and so does proteasomal 
degradation of YAP1. Accumulating YAP1 then can translo-
cate to the nucleus where it acts—in concert with TAZ—as 
a transcriptional coactivator to promote the expression of its 
target genes such as Birc5 or Ctgf.5 The release of YAP1 ac-
tivity usually is associated with cell cycle entry and apoptotic 
suppression resulting in an enlarged organ.5
In the liver, the transgenic overexpression of YAP1 or 
liver‐specific deletion of MST/LATS causes hepatomeg-
aly that, however, is reversible upon YAP1 inactivation.5,6 
Furthermore, cholestatic injury in YAP1‐deficient mouse 
liver is associated with excessive necrosis,7 consistent with 
a proregenerative function of the protein. In mouse liver 
following sHx, YAP1 but not TAZ activity (ie, nuclear ex-
pression and target gene expression) increases while MST/
LATS activities decrease, followed by a return to baseline lev-
els upon completion of regeneration.7,8 Elevated MST/LATS 
activities have further been found to be responsible for the re-
generative deficits of aged liver.9 Besides its generic control 
through the Hippo pathway, YAP1 is also promoted through 
hedgehog signaling during regeneration, with hedgehog in-
hibition impacting both hepatocyte proliferation and YAP1 
activation.10 In a recent report, liver‐specific YAP1 knockout 
was associated with reduced Ki67 counts at 48 hours after 
hepatectomy11; however, no further proliferative parameters 
or time points were analyzed.
Collectively, the above findings suggest YAP1 activity is 
required after tissue loss for a liver to regenerate. However, 
available evidence remains largely associative or is insuffi-
cient to provide clear insight into the role of YAP1 in the 
regenerating liver. To appreciate the function of YAP1 in pa-
renchymal regeneration, its acute loss in hepatocytes may be 
a suitable strategy as to minimize compensatory mechanisms 
or pre‐existing pathologies.12,13 To this end, we used a nano-
formulation to achieve hepatocyte‐specific knockdown of 
YAP1 in a mouse model of standard hepatectomy. Moreover, 
we compared outcomes with an established model of resec-
tion‐induced liver failure and validated findings in human 
liver tissue.
2 |  MATERIALS AND METHODS
2.1 | Animals
Animals aged 8‐10 weeks were kept on a 12‐hour day/
night cycle with free access to standard chow and water. 
Littermates were housed in ventilated cages with automated 
ambient regulation at room temperature in an environment 
enriched with paper and bedding for nesting. Male wild‐type 
mice (C57BL6, Envigo, Horst, NL) were used.
2.2 | Animal surgery
Standard hepatectomies (sHx, 70%, fully regenerating, 100% 
survival) and extended hepatectomies (eHx, 86%, regenera-
tive delay, ~70% survival, SFSS model) were performed as 
reported.2 Sham operation consisted of cholecystectomy. The 
gain in liver weight, a physical measure of liver regeneration, 
was expressed through the ratio of liver‐weight‐to‐body‐
weight (LW/BW).
K E Y W O R D S
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2.3 | Yap1 knockdown
siRNAs targeting Yap1 and the control Ahsa1 (ie, without 
regenerative function) were designed by Axolabs Gmbh 
(Kulmbach, D) and packed into company‐owned formula-
tions designed to preferentially target murine hepatocytes. 
Formulations were injected into the tail vein 48 hours before 
hepatectomy. The lack of significant toxicity was ascertained 
through the assessment of liver injury markers.
2.4 | Immunochemistry
Immunostainings were performed on 3‐μm formalin‐fixed, 
paraffin‐embedded liver sections. Antigenes were retrieved 
by boiling in citrate buffer. The following primary antibodies 
were used: Ki67 (Abcam, Cambridge, UK; ab16667), pH3 
(Abcam; ab92628), YAP1 (Santa Cruz, Santa Cruz, CA, 
USA; sc‐15407), PCNA (Abcam; ab29). Secondary detection 
was done using the Ventana Discovery automated staining 
system and the iView DAB kit (Ventana Medical Systems, 
Basel, CH). Blinded counts were from 10 random fields (20× 
magnification) per sample. Biopsy tissue was obtained from 
hepatectomy patients without postoperative complications 
(n = 7, normally regenerating liver, retrieved at day 7 (3), 
day 8 (1), day 9 (2), and day 11 (1) postsurgery), and from 
hepatectomy patients that had developed SFSS (n = 7, SFSS, 
retrieved at day 5 (1), day 7 (1), day 9 (2), day 10 (1), day 
12 (1), and day 14 (1) postsurgery). The clinical diagnosis of 
SFSS was based on the “50‐50 criteria.”14
2.5 | Quantitative real‐time polymerase 
chain reaction
Total RNA was extracted from 20 mg of liver tissue using 
TRIzol reagent (Invitrogen, Zug, CH) and transcribed into 
cDNA using the ThermoScript reverse‐transcription PCR 
System (Invitrogen). TaqMan gene expression assays for 
Ccnd1 (Mm00432359_m1), Ccne1 (Mm00432367_m1), 
Ccna2 (Mm00438064_m1), Ccnb2 (Mm01171453_m1), 
Yap1 (Mm01143263_m1), Ctgf (Mm01192932_g1), Birc5 
(Mm00599749_m1), Myc (Mm00487803_m1), Cyr61 
(Mm00487498_m1), and 18S rRNA internal control 
(TaqMan ribosomal RNA control reagents) were from PE 
Applied Biosystems (Rotkreuz, CH). The results represent 
fold induction (2−∆Ct) of mRNA expression ±SD.
2.6 | Serum measurements
Serum samples were obtained from the inferior vena cava 
before organ harvesting. Albumin, bilirubin, ALT, AST, 
ALKP, and LDH levels were measured using a serum mul-
tiple biochemical analyzer (Dri‐Chem 4000i, Fujifilm, 
Dielsdorf, CH).
2.7 | Western blotting
Western blot was performed as described previously.2 The fol-
lowing primary antibodies were used: YAP1 (Cell Signalling, 
Beverly, MA, USA; 4912) and GAPDH (Abcam ab9484).
2.8 | Statistical analysis
Data are presented as mean ± SD. Differences between the 
groups were assessed by a two‐tailed t test assuming unequal 
variance. At least 5 mice/group were analyzed unless oth-
erwise stated. For the molecular analyzes following siRNA 
knockdown, ≥ 3 mice/group were included. Differences 
were considered significant at P < 0.05 and indicated in fig-
ures by an asterisk (*). Statistical analyzes were performed 
using Prism 6.0 (GraphPad, La Jolla, CA).
2.9 | Study approval
All animal experiments were in accordance with Swiss Federal 
Animal Regulations and approved by the Veterinary Office of 
Zurich. Ethical approval for the human sections was granted 
by the regional ethics committee (KEK‐ZH‐Nr 2012‐01 08). 
A written consent to study tissue for research purposes was re-
ceived from the patient prior to inclusion in the study.
3 |  RESULTS
3.1 | Hepatocellular YAP1 is activated 
during the major proliferative wave after 
resection
YAP1 has been reported to be upregulated in liver after tissue 
loss.8,10 To confirm its elevation in our model of standard 70%‐
hepatectomy (sHx), we assessed hepatic Yap1 mRNA at various 
times after resection. Relative to sham operation, Yap1 expres-
sion rose at 32 hours (P = 0.053) and 48 hours (P < 0.05) post‐
sHx, and declined again at 96 hours to baseline levels (Figure 
1A). Immunoblots confirmed YAP1 protein upregulation at 
32 hours and 48 hours (Figure 1B), the usual S‐ and M‐phase 
peaks after sHx.8 Increased protein levels were accompanied 
by nuclear translocation of YAP1 (Figure 1B), and an elevated 
expression of its transcriptional targets Ctgf, Birc5, Cyr61, and 
Myc relative to sham controls (Figure 1C). Therefore, YAP1 
appears to be activated during the major growth phase of the 
regenerating mouse liver after resection.
3.2 | YAP1 knockdown impairs liver 
regeneration at 32 hours but not 48 hours after 
hepatectomy
To explore the contribution of YAP1 to the major paren-
chymal growth phase during regeneration, we performed 
54 |   TSCHUOR eT al.
a knockdown experiment. αAhsa1‐ (hepatic control) and 
αYap1‐siRNA were intravenously injected 48 hours prior 
to sHx using a nanoformulation that preferentially targets 
hepatocytes.3,15 Knockdown was effective at 32 hours post‐
sHx, as demonstrated through significantly reduced levels of 
Yap1 mRNA, YAP1 protein, and of its transcriptional targets 
Ctgf, Birc5, and Myc (Figure 2A). Importantly, knockdown 
was limited to hepatocytes, sparing non‐parenchymal liver 
cells and extrahepatic tissues such as colon (Supplementary 
Figures 1-3), confirming the selectivity of the formulation. 
Similarly, knockdown was effective at 48 hours post‐sHx, 
with reductions in both Yap1 and hepatocellular YAP1 
akin to 32 hours (Figure 2B, Supplementary Figures 1-3). 
Notably, however, the transcriptional targets of YAP1 were 
upregulated at 48 hours post‐sHx in αYap1‐siRNA‐treated 
mice relative to αAhsa1‐siRNA‐treated or untreated mice 
(Figure 2B), suggesting YAP1 is no more the main transcrip-
tional regulator of investigated target genes at this time in 
the regenerating liver. Of further note, neither histology nor 
serum markers indicated ponderable liver injury with the 
knockdown, suggesting no confounding damage is present 
(Supplementary Figure S4).
To determine the effects of YAP1 deficiency on the re-
generative process, we measured the liver weight gain (LW/
BW) after siRNA treatment and resection. Interestingly, LW/
BW tended to be reduced (P = 0.086) already at hepatectomy 
in αYap1‐siRNA‐ relative to αAhsa1‐siRNA‐treated mice 
(Figure 2C), consistent with the role of YAP1 as a physiolog-
ical regulator of resting liver size.5 Remarkably, liver weight 
gain was completely suppressed up to 32 hours after sHx; at 
48 hours, liver weight still was reduced compared to controls, 
however, the regain was accelerated toward 48 hours in mice 
with Yap1 knockdown compared to controls (Figure 2C). 
Therefore, YAP1 is required for early regeneration, but ap-
pears to be dispensable for later liver growth, consistent with 
the dissociation of nuclear YAP1 from its transcriptional tar-
gets at 48 hours post‐sHx (Figures 1C and 2B). Nonetheless, 
1‐week survival (ie, the best measure for a functional liver 
recovery) appeared to be slightly compromised (P = 0.09) 
after Yap1 knockdown and hepatectomy (Figure 2C), sug-
gesting that the early promotion of liver weight gain (ie, up to 
32 hours) through YAP1 is vital to regeneration after tissue 
loss. Finally, the macroscopic appearance of αYap1‐siRNA‐
treated liver was pale at 48 hours after sHx (Figure 2C), 
F I G U R E  1  YAP1 is induced during the major parenchymal growth phase after hepatectomy. (A) Yap1 mRNA expression after sHx or sham 
surgery. (B) YAP1 protein expression at 32 hours and 48 hours after sHx/sham assessed by immunoblots and immunohistochemistry. Note the 
nuclear accumulation after sHx. (C) YAP1 target gene expression after sHx/sham. N = 5/group, t test, *P < 0.05
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pointing to persisting steatosis that typifies liver remnants 
with a regenerative deficiency.2,3,16
3.3 | YAP1 knockdown affects proliferative 
markers and cell cycle molecules at 32 hours 
but not 48 hours after hepatectomy
To further characterize the regenerative deficits following 
Yap1 knockdown, we assessed parameters of proliferation 
and liver function.
Relative to control siRNA, Yap1 knockdown prior to sHx 
resulted in a suppression of hepatocytes positive for Ki67 
(marking cycling cells) pH3 (G2/M‐phase cells), or for his-
tological mitosis, while PCNA counts (S‐phase cells) were 
strongly reduced at 32 hours, the usual S‐phase peak after 
sHx (Figure 3A). Furthermore, histological steatosis was pro-
nounced upon Yap1 knockdown (Figure 3A, Supplementary 
Figure S4), consistent with the macroscopic liver appear-
ance (Figure 2C). The expression of Ccnd1 and Ccne1 was 
unaffected; however, both Ccna2 and Ccnb2 were markedly 
downregulated through αYap1‐siRNA (Figure 3A). Serum 
albumin was reduced, while bilirubin levels remained un-
changed following Yap1 knockdown (Figure 3A), indicating 
some liver dysfunction with YAP1 deficiency.
At 48 hours (the usual M‐phase peak) after hepatectomy, 
Ki67 counts were similar and PCNA counts tended (P = 0.1) 
to increase in αYap1‐siRNA‐ vs αAhsa1‐siRNA‐treated mice, 
while pH3 positivity and mitotic counts were reduced, but 
no more suppressed as at 32 hours, in Yap1‐deficient liver 
(Figure 3B). These findings suggest that YAP1 deficiency 
causes an initial proliferative block (eg, evident at 32 hours), 
which is followed by tardive, compensatory proliferation of 
hepatocytes independent of YAP1 at 48 hours post‐resection. 
In agreement, Ccna2 and Ccnb2 expression were upregulated 
(Figure 3B) despite YAP1 knockdown at 48 hours (Figure 
2B), while Ccnd1/Ccne1 expression stayed unaffected. 
Histological steatosis remained more pronounced and albu-
min reduced in αYap1‐siRNA‐treated animals, reflecting an 
F I G U R E  2  Yap1 knockdown impairs 
liver regeneration up to 32 hours following 
sHx. (A) Yap1 mRNA, YAP1 protein, and 
target gene expression at 32 hours following 
sHx, sHx plus αAhsa1‐siRNA, and sHx 
plus αYap1‐siRNA. (B) Yap1 mRNA, 
YAP1 protein, and target gene expression 
at 48 hours after sHx and siRNA treatment. 
Note the upregulation for three out of four 
YAP targets with αYap1‐siRNA treatment 
N = 3/group, t test, *P < 0.05. (C) LW/BW 
and 7‐day survival in αAhsa1‐siRNA‐ and 
αYap1‐siRNA‐treated mice after sHx. N = 5/
group, t test, *P < 0.05. Macroscopic liver 
appearance at 48 hours is shown to the right
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impaired function—likely because of the still smaller rem-
nant relative to controls at 48 hours (Figure 2C).
Based on the findings shown in Figures 2 and 3, we con-
clude that YAP1 is essential for hepatocytes to enter the 
cell cycle and progress through the S‐phase (ie, 32 hours). 
For further progression (ie, 48 hours), YAP1 is no more 
needed, either due to compensatory mechanisms elicited 
through the Yap1 knockdown, or because its physiological 
F I G U R E  3  Proliferative and metabolic parameters following knockdown and sHx. (A) Top: immunohistochemistry for Ki67, PCNA, 
pH3, and histological (H&E) steatosis (Ki67/PCNA/pH3/mitotic counts to the right). Bottom: cyclin gene expression, serum albumin, and serum 
bilirubin; all at 32 hours following sHx and siRNA treatment. (B) The same parameters as for A at 48 hours following sHx and siRNA treatment. 
Note the attenuation of effects in the proliferative parameters and the upregulation of Ccna2/b2 in αYap1‐siRNA‐treated mice. N = 5/group, t test, 
*P < 0.05
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role is limited to the G0 > G1 > S‐promotion during liver 
regeneration.
3.4 | YAP1 is downregulated during earlier, 
but not later stages of resection‐induced 
liver failure
To get better insight into the physiological role of YAP1 
during liver regeneration, we examined its expression after 
extended hepatectomy (eHx). Liver failure after eHx devel-
ops due to deficient progression through the hepatocellular 
S‐ and M‐phases associated with a shutdown of pro‐prolif-
erative pathways.2,3,16 If YAP1 indeed functions in the early 
cell cycle (including the S‐phase) but is dispensable for the 
M‐phase, its activity should be impaired at 32 hours, but not 
48 hours, after eHx.
When comparing sHx vs eHx relative to sham surgery, 
YAP1 protein expression was elevated at 32 hours after sHx, 
but remained at sham levels after eHx (Figure 4A). Likewise, 
YAP1 nuclear accumulation was reduced at 32 hours after 
eHx relative to sHx (Figure 4A). YAP1 thus is not upregu-
lated when S‐phase progression is defective, concordant with 
a role in promoting the earlier cell cycle stages (Figures 2C 
and 3A). At 48 hours, however, YAP1 protein was similarly 
elevated and displayed comparable nuclear accumulation 
after both sHx and eHx (Figure 4B). Given that transient 
arrest at the M‐phase is the most defining cell cycle defect 
in resection‐induced liver failure,2,3,16 nuclear YAP1 cannot 
be associated with the regulation of the M‐phase in these 
settings. This finding is consistent with the reprise of liver 
weight gain (Figure 2C) and proliferative activity (Figure 3B) 
seen at 48 hours post‐sHx despite YAP1 knockdown (Figure 
2B). Therefore, compensatory mechanisms triggered through 
the acute YAP1 deficiency are unlikely causal in dissociat-
ing YAP1 activity from regeneration at 48 hours post‐sHx. 
Rather, YAP1’s key physiological role in liver regeneration is 
the initial promotion of the hepatocyte cycle to and through 
the S‐phase, while the M‐phase may be governed through 
other pathways with redundant downstream targets.
3.5 | YAP1 is induced in human liver 
regeneration
To validate a physiological role of YAP1 in liver regenera-
tion, we examined biopsy material retrieved from human 
liver before and after hepatectomy. Biopsies were available 
from patients (n = 7, 7‐11 days postsurgery) that recovered 
from hepatectomy without complications (ie, successful re-
generation) and from patients (n = 7, 5‐14 days postsurgery) 
that developed the SFSS (ie, resection‐induced liver failure). 
We previously have shown that human SFSS features similar 
characteristics as its mouse counterpart, namely deficient cell 
cycle progression, downregulation of the cell cycle promoter 
FOXM1, upregulation of P21, metabolic insufficiency (per-
sisting steatosis, hypoalbuminemia, hyperbilirubinemia), and 
an elevated mortality.2,3 When examining YAP1 by immuno-
histochemistry, the protein displayed little expression in rest-
ing liver before hepatectomy, but was markedly upregulated 
(including nuclear expression) in regenerating human liver 
(Figure 5). In contrast, YAP1 nuclear expression was reduced 
in human SFSS liver relative to regenerating liver (Figure 5). 
No information, however, was available on the particular cell 
cycle phases of investigated human livers. Nonetheless, these 
findings strongly suggest that YAP1 contributes to the suc-
cessful regeneration of human liver after hepatectomy.
4 |  DISCUSSION
Given the role of YAP1 in organ size control, a function for 
the transcriptional coactivator in liver regeneration has been 
anticipated. Available data support this view,7-12 however, 
F I G U R E  4  YAP1 protein 
expression during resection‐induced liver 
failure. Quantified YAP1 expression, 
corresponding immunoblots, and YAP1 
immunohistochemistry at 32 hours (A) and 
48 hours (B) after sHx and eHx. eHx was 
compared to sHx, revealing a significant 
downregulation of YAP1 at 32 hours, but 
not at 48 after eHx. Note the low nuclear 
expression of YAP1 at 32 hours after eHx. 
The differences between sham and sHx at 
32 hours and sHx/eHx at 48 hours were 
significant as well (see Figure 1B). N = 5/
group, t test, *P < 0.05
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the need of YAP1 for the liver to regenerate has remained 
ill‐proven. Here, we show that liver regeneration in mice is 
stalled for the first 32 hours after tissue loss when YAP1 is 
inhibited; however, liver weight regain is resumed thereafter. 
The pro‐regenerative role of YAP1 is thus confined to the 
progression of hepatocytes into cycle and through the S‐
phase, but is expendable for a further progression through 
the M‐phase. Such a role is reflected in resection‐induced 
F I G U R E  5  YAP1 
immunohistochemistry on human liver 
tissue. Representative examples of resting, 
regenerating, and SFSS liver each of three 
different patients (A, B, and C) are shown. 
Immunochemistry for pH3 was included to 
illustrate the regenerative state. See Methods 
for patient characteristics. Although 
data on the time of biopsy retrieval were 
available, no associations with specific cell 
cycle phases were possible, as cell cycle 
progression is heterogeneous and strongly 
dependent on the disease background and 
the state of patients' livers
Resting Regeneration SFSS
ph
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liver failure with deficient S‐ and M‐phase progression, 
where YAP1 fails to be induced during the S‐phase peak, but 
is upregulated during the M‐phase. Finally, YAP1 may have 
a similar function in human liver regeneration, as evinced 
through the examination of clinical samples.
Confirming its peak expression at 32‐48 hours after 
hepatectomy,8,10 we chose a knockdown approach to probe 
YAP1’s function. Acute deficiency may avoid compensation 
through other proteins such as YAP1’s partner TAZ, which 
is upregulated in YAP1 knockout liver.13 Knockdown was 
effective during the expression peak at both the mRNA and 
protein level. However, as a limitation, we cannot exclude 
off‐target effects even though the siRNA used was selected 
among 12 sequences designed to have no homology to other 
genomic sequences (Axolabs Gmbh). On the other hand, no 
systemic or cell‐unspecific effects are expected, as siRNA 
was delivered through a nanoformulation that we confirmed 
to specifically target hepatocytes (Figures S1‐S3).3,15
Our findings of YAP1 as a promoter of the early he-
patocyte cell cycle are consistent with its generic function 
in proliferation. Following mechanical tension or the loss of 
cell‐cell contacts, YAP1 fosters cell cycle entry and progres-
sion through the S‐phase.17,18 Although YAP1’s cell cycle 
functions may be divergent,19 the regulation up to the S‐phase 
is a recurring feature.20 The defects in cell cycle entry (Ki67) 
and the S‐phase (Ccna2, PCNA) upon knockdown conceiv-
ably explain the lack of liver weight regain up to 32 hours 
after sHx. However, Ccnd1/e1 expression was unaffected, 
perhaps implying YAP1 regulates cell cycle entry in regen-
erating liver via other molecules such as the E2F‐dependent 
transcriptional network.21
Contrary to our findings, Lu et  al12 have observed only 
slight impairment of early regeneration in mouse liver with 
constitutive YAP1/TAZ deletion, while major defects were 
noted between 7 and 14 days after sHx. These double‐knock-
out‐livers, however, displayed several chronic pathologies, 
including ill‐developed bile ducts, inflammation, parenchy-
mal injury, hepatomegaly, and neoplastic changes. Therefore, 
the elevated basal proliferation seen in YAP1/TAZ−/− livers 
may have masked early regenerative defects, while the pre‐
existing parenchymal injury may have exaggerated regener-
ative deficiencies over time. An alternative explanation for 
the divergent outcomes may be the concomitant loss of TAZ 
in their model.12 In another recent report, liver‐specific Yap1 
knockout (induced by adenoviral Cre) has resulted in reduced 
Ki67 counts (by ~50%) at 48 hours post‐hepatectomy.11 We 
could not confirm this finding, possibly because the knockout 
strategy was more efficient than our knockdown in reduc-
ing YAP1 levels, leading to a more severe initial delay that 
left more traces at 48 hours post‐sHx. Comparisons with the 
Yap1 knockout model however remain difficult, because only 
one marker at one time point has been assessed in the latter.11 
Anyhow, our approach of acute deficiency induced prior to 
hepatectomy demonstrates that YAP1’s specific contribution 
is vital for early but dispensable for later stages of liver regen-
eration, a finding corroborated with our liver failure model.
Intriguingly, Ki67, PCNA, cyclins and YAP targets were 
re‐elevated at the mitotic peak (48 hours) after sHx despite 
effective knockdown, suggesting a contribution of other pro‐
regenerative transcriptional activators. β‐catenin, for exam-
ple, is thought to be inhibited by YAP1 in the liver,5 promotes 
regeneration, and can likewise activate the YAP1 targets 
Birc5, Ctgf, Cyr61, and Myc in hepatic cells.22-25 Indeed, 
we observed increased nuclear β‐catenin expression upon 
YAP1 knockdown at 48 hours after sHx (Supplementary 
Figure S5), consistent with a reduced inhibition of β‐catenin5 
leading to increased promotion of the transcriptional targets 
shared with YAP1. The upregulation of β‐catenin in response 
to YAP1 deficiency perhaps reflects the redundant mitogenic 
pathways that ensure recovery also under suboptimal condi-
tions—a key principle behind liver regeneration.26
In keeping with the above, our model of resection‐induced 
liver failure was associated with a re‐elevation of YAP1 at 
48 hours despite its defective induction at 32 hours. Liver 
fails after eHx particularly because of a p21‐dependent arrest 
before mitosis, with compensatory regeneration starting not 
before 24 hours later.2 Therefore, the upregulation at 48 hours 
after eHx confirms the dissociation of YAP1 from mitotic 
progression during liver regeneration. Notably, the inhibi-
tion of both S‐phase and M‐phase progression prior to sHx 
induces full SFSS symptoms (steatosis, hypoalbuminemia, 
hyperbilirubinemia, increased mortality) akin to eHx.3 In 
contrast, sHx in YAP1‐deficient mice caused only mild SFSS 
(normal bilirubin, mild steatosis, slightly reduced mortality), 
again entirely consistent with a defect limited to the S‐phase. 
If not promoting tissue growth at 48 hours post‐sHx, why is 
YAP1 upregulated then? Metabolic functions of YAP15 per-
haps might provide a conjectural explanation: recently, YAP1 
has been reported to promote glycolysis,27,28 a function that 
may contribute to the switch from lipids to glucose as a pref-
erential energy source observed after 48 hours in the regen-
erating liver.16 Alternatively, YAP1 may contribute to the 
remodeling of the extracellular matrix, an obligate event in 
regenerating liver.26 Recent data indicate YAP1 promotes the 
acquisition of mesenchymal traits, enabling regenerating he-
patocytes to produce fibrous matrix particularly at later times 
after hepatectomy11—a potential contribution to the reconsti-
tution of the extracellular liver environment.
In summary, we report an essential role for YAP1 in pro-
moting hepatocyte cell cycle progression to and through the 
S‐phase in regenerating liver after tissue loss. Our findings 
further suggest additional, however, non‐proliferative, func-
tions of YAP1 during later regenerative phases when hepato-
cyte mitosis peaks. These observations were corroborated 
in regenerative failure typified through deficient S‐ and M‐
phase progression, where YAP1 is downregulated only at the 
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S‐ but not the M‐phase peak. Akin to the mouse liver, YAP1 
was induced in human livers with successful regeneration, 
but not in those with failed regeneration, suggesting YAP1’s 
role in liver regeneration is conserved in mammals. Future 
research should address whether pharmacological YAP1 ac-
tivators currently in development29 may bear potential to aid 
liver regeneration in the clinic.
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